Drug intelligence / Profile preview

DA-4533

Development stage: Preclinical
Lead developer: Dong-A ST
Modality: Small Molecules

Overview

DA-4533 is a small molecule oncology candidate currently in the preclinical stage of development by the South Korean pharmaceutical company Dong-A ST. As a part of the company's research and development pipeline in the field of oncology, DA-4533 is being evaluated for its potential as a targeted therapy for various cancers. Although the specific molecular target and mechanism of action have not been publicly disclosed by Dong-A ST, the asset is part of a broader effort to develop innovative treatments for solid tumors and hematological malignancies. The compound is currently undergoing preclinical evaluation to determine its efficacy and safety profile before potentially advancing to human clinical trials.

Beyond the preview

Go deeper on DA-4533.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DA-4533.

Explore the full profile